flt3突变急性髓系白血病干细胞移植后酪氨酸激酶抑制剂维持治疗。

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2025-04-28 DOI:10.1002/14651858.CD016090

Po-Huang Chen, Hong-Jie Jhou, Cho-Hao Lee

引用次数: 0

摘要

目的：这是Cochrane综述（干预）的一个方案。目的如下：评估FLT3 TKIs作为维持治疗的效果，与无维持治疗或替代策略相比，FLT3突变AML患者在同种异体造血干细胞移植后的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tyrosine kinase inhibitor maintenance therapy after stem cell transplantation for FLT3-mutated acute myeloid leukemia.

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of FLT3 TKIs as maintenance therapy compared to no maintenance therapy or alternative strategies for participants with FLT3-mutated AML after allo-HSCT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.